{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:37:04Z","timestamp":1793317024136,"version":"4.5.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Chinese medicine has a unique theory and the Chinese herbal medicine treatment is based on the integral concepts and syndrome differentiation of the Traditional Chinese Medicine system. Although antibiotics remain the mainstay of SIBO treatment, various alternative or adjunctive therapies are available, including prokinetic agents, dietary interventions, probiotics, and herbal combinations. There is accumulating evidence demonstrating the antimicrobial properties of a growing number of herbs including garlic, black cumin, cloves, cinnamon, thyme, all-spices, bay leaves, mustard, and rosemary. This has prompted an interest in herbal therapy for the treatment of SIBO. Currently, there is no systematic review focusing on efficacy of CHM in the treatment of SIBO with PCOS, so our meta-analysis aims to comprehensively explore it. Meanwhile we will provide high-quality evidence to help patients, clinicians as well as health policymakers select better treatment strategy of PCOS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We will search the following sources without restrictions for date, language, or publication status: PubMed, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL) Cochrane Library, EMBASE and China National Knowledge Infrastructure. We will apply a combination of Medical Subject Heading (MeSH) and free-text terms incorporating database-specific controlled vocabularies and text words to implement search strategies. We will also search the ongoing trials registered in the World Health Organization's International Clinical Trials Registry Platform. Besides, the previous relevant reviews conducted on CHM for SIBO and reference lists of included studies will also be searched.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>This study will provide a reliable basis for the treatment of SIBO with CHM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The findings will be an available reference to evaluate the efficacy and safety of CHM in the treatment of SIBO.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Registration number:<\/jats:title>\n            <jats:p>INPLASY202080004.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000023737","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T21:46:20Z","timestamp":1608241580000},"page":"e23737","source":"Crossref","is-referenced-by-count":7,"title":["Chinese herbal medicine for the treatment of small intestinal bacterial overgrowth (SIBO)"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6151-1013","authenticated-orcid":false,"given":"Xuetong","family":"Ren","sequence":"first","affiliation":[{"name":"Hebei University of Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Di","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang City, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hebei University of Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqian","family":"Fu","sequence":"additional","affiliation":[{"name":"Hebei University of Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuman","family":"Wang","sequence":"additional","affiliation":[{"name":"Hebei University of Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongxin","family":"Huang","sequence":"additional","affiliation":[{"name":"Hebei University of Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Du","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang City, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"R1-20240318","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/apt.12531","article-title":"Commentary: Towards an effective and safe treatment of small intestine bacterial overgrowth","volume":"38","author":"Scarpignato","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R2-20240318","first-page":"112","article-title":"Small intestinal bacterial overgrowth: a comprehensive review","volume":"3","author":"Dukowicz","year":"2007","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R3-20240318","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/MOG.0000000000000040","article-title":"Small intestinal bacterial overgrowth: what it is and what it is not","volume":"30","author":"Quigley","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"key":"R4-20240318","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.13928","article-title":"Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth","volume":"45","author":"Gatta","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R5-20240318","article-title":"Small intestinal bacterial overgrowth: clinical presentation in patients with Roux-en-Y gastric bypass","author":"Dolan","year":"2020","journal-title":"Obes Surg"},{"key":"R6-20240318","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.gtc.2020.04.010","article-title":"Small intestinal bacterial overgrowth: how to diagnose and treat (and Then Treat Again)","volume":"49","author":"Ginnebaugh","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"key":"R7-20240318","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/nmo.12516","article-title":"Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test","volume":"27","author":"Erdogan","year":"2015","journal-title":"Neurogastroenterol Motil"},{"key":"R8-20240318","article-title":"Small intestinal bacterial overgrowth syndrome: a guide for the appropriate use of breath testing","author":"Massey","year":"2020","journal-title":"Dig Dis Sci"},{"key":"R9-20240318","article-title":"Alternative treatment approaches to small intestinal bacterial overgrowth: a systematic review","author":"Nickles","year":"2020","journal-title":"J Altern Complement Med"},{"key":"R10-20240318","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.3748\/wjg.v16.i24.2978","article-title":"Small intestinal bacterial overgrowth syndrome","volume":"16","author":"Bures","year":"2010","journal-title":"World J Gastroenterol"},{"key":"R11-20240318","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1365-2036.2011.04625.x","article-title":"Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture","volume":"33","author":"Choung","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R12-20240318","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/ajg.2017.46","article-title":"Hydrogen and methane-based breath testing in gastrointestinal disorders: the north american consensus","volume":"112","author":"Rezaie","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R13-20240318","doi-asserted-by":"crossref","first-page":"e00078","DOI":"10.14309\/ctg.0000000000000078","article-title":"Small intestinal bacterial overgrowth: clinical features and therapeutic management","volume":"10","author":"Rao","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"R14-20240318","doi-asserted-by":"crossref","first-page":"165","DOI":"10.14309\/ajg.0000000000000501","article-title":"ACG clinical guideline: small intestinal bacterial overgrowth","volume":"115","author":"Pimentel","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"R15-20240318","first-page":"1334","article-title":"The prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome: IBS vs healthy controls (not historical definitions)","volume":"57","author":"Pimentel","year":"2008","journal-title":"Gut"},{"key":"R16-20240318","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/apt.15133","article-title":"Systematic review with meta-analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease","volume":"49","author":"Shah","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R17-20240318","article-title":"Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms","volume":"32","author":"Tauber","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"R18-20240318","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000444436","article-title":"Changes of intestinal functions in liver cirrhosis","volume":"1","author":"Fukui","year":"2016","journal-title":"Inflamm Intest Dis"},{"key":"R19-20240318","doi-asserted-by":"crossref","first-page":"159","DOI":"10.15403\/jgld.2014.1121.252.iwg","article-title":"Small intestinal bacterial overgrowth is associated with non-alcoholic fatty liver disease","volume":"25","author":"Fialho","year":"2016","journal-title":"J Gastrointestin Liver Dis"},{"key":"R20-20240318","first-page":"1","article-title":"Chinese herbal medicine in treatment of spinal cord injury: a systematic review and meta-analysis of randomized controlled trials","author":"Zheng","year":"2020","journal-title":"Am J Chin Med"},{"key":"R21-20240318","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.2174\/0929867043365107","article-title":"Antimicrobial and chemopreventive properties of herbs and spices","volume":"11","author":"Lai","year":"2004","journal-title":"Curr Med Chem"},{"key":"R22-20240318","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P): elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R23-20240318","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2036.2005.02516.x","article-title":"Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth","volume":"22","author":"Lauritano","year":"2005","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T11:11:36Z","timestamp":1710760296000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023737"}},"subtitle":["A protocol for systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":23,"journal-issue":{"issue":"51","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000023737","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]}}}